IRIS Accounts Production v25.1.3.33 01823324 director 1.11.23 31.10.24 31.10.24 No description of principal activity 0 0 false true false false false true true Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh018233242023-10-31018233242024-10-31018233242023-11-012024-10-31018233242022-10-31018233242022-11-012023-10-31018233242023-10-3101823324ns15:EnglandWales2023-11-012024-10-3101823324ns14:PoundSterling2023-11-012024-10-3101823324ns10:Director12023-11-012024-10-3101823324ns10:PrivateLimitedCompanyLtd2023-11-012024-10-3101823324ns10:SmallEntities2023-11-012024-10-3101823324ns10:AuditExempt-NoAccountantsReport2023-11-012024-10-3101823324ns10:SmallCompaniesRegimeForDirectorsReport2023-11-012024-10-3101823324ns10:SmallCompaniesRegimeForAccounts2023-11-012024-10-3101823324ns10:FullAccounts2023-11-012024-10-310182332412023-11-012024-10-3101823324ns10:OrdinaryShareClass12023-11-012024-10-3101823324ns10:CompanySecretary12023-11-012024-10-3101823324ns10:RegisteredOffice2023-11-012024-10-3101823324ns5:ShareCapital2024-10-3101823324ns5:ShareCapital2023-10-3101823324ns5:RetainedEarningsAccumulatedLosses2024-10-3101823324ns5:RetainedEarningsAccumulatedLosses2023-10-3101823324ns5:NetGoodwill2023-11-012024-10-3101823324ns5:IntangibleAssetsOtherThanGoodwill2023-11-012024-10-3101823324ns5:NetGoodwill2023-10-3101823324ns5:NetGoodwill2024-10-3101823324ns5:NetGoodwill2023-10-3101823324ns10:OrdinaryShareClass12024-10-31
REGISTERED NUMBER: 01823324 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 October 2024

for

Globepharm Limited

Globepharm Limited (Registered number: 01823324)






Contents of the Financial Statements
for the Year Ended 31 October 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3

Globepharm Limited

Company Information
for the Year Ended 31 October 2024







Director: J N Bleby





Secretary: J N Bleby





Registered office: 76 Dunsfold Park
Stovolds Hill
Cranleigh
Surrey
GU6 8TB





Registered number: 01823324 (England and Wales)

Globepharm Limited (Registered number: 01823324)

Balance Sheet
31 October 2024

2024 2023
Notes £ £
Total assets less current liabilities - -

Capital and reserves
Called up share capital 5 100 100
Retained earnings (100 ) (100 )
Shareholders' funds - -

The company is entitled to exemption from audit under Section 480 of the Companies Act 2006 for the year ended 31 October 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 October 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 19 June 2025 and were signed by:





J N Bleby - Director


Globepharm Limited (Registered number: 01823324)

Notes to the Financial Statements
for the Year Ended 31 October 2024

1. Statutory information

Globepharm Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Accounting policies

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business, is being amortised evenly over its estimated useful life of 5 years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Going concern
The company has no assets and is reliant on the continuing support of the director.

3. Employees and directors

The average number of employees during the year was NIL (2023 - NIL).

4. Intangible fixed assets
Goodwill
£
Cost
At 1 November 2023
and 31 October 2024 840
Amortisation
At 1 November 2023
and 31 October 2024 840
Net book value
At 31 October 2024 -
At 31 October 2023 -

Globepharm Limited (Registered number: 01823324)

Notes to the Financial Statements - continued
for the Year Ended 31 October 2024

5. Called up share capital

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £ £
100 Ordinary £1.00 100 100